CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses
The development of oncolytic viruses has led to an emerging new class of cancer therapeutics. Although the safety profile has been encouraging, the transition of oncolytic viruses to the clinical setting has been a slow process due to modifications. Therefore, a new generation of more potent oncolyt...
Main Authors: | Ming Yuan, Eika Webb, Nicholas Robert Lemoine, Yaohe Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-03-01
|
Series: | Viruses |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4915/8/3/72 |
Similar Items
-
Developing oncolytic Herpes simplex virus type 1 through UL39 knockout by CRISPR-Cas9
by: saeedeh Ebrahimi, et al.
Published: (2020-07-01) -
Oncolytic Virotherapy for Cancer: Clinical Experience
by: Shyambabu Chaurasiya, et al.
Published: (2021-04-01) -
Oncolytic virotherapy for pediatric malignancies: future prospects
by: Waters AM, et al.
Published: (2016-08-01) -
Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles
by: Yaohe Wang, et al.
Published: (2010-01-01) -
Engineering and Characterization of Oncolytic Vaccinia Virus Expressing Truncated Herpes Simplex Virus Thymidine Kinase
by: S. M. Bakhtiar Ul Islam, et al.
Published: (2020-01-01)